Journal: bioRxiv

Article Title: The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer

doi: 10.1101/2023.09.08.556819

Figure Lengend Snippet: (A) Basal heparan sulfate expression was examined in the supernatants of TNBC cells and control immortal MCF-10A via ELISA analysis with MDA-MB 468 expressing the most. The standard deviation was calculated from three independent experiments performed in triplicate. The student’s t-test was performed to determine the significance with * representing p<0.05 and ** representing p<0.01 the protein expression in MCF-10A to the protein expressions in the TNBC cell lines. (B) Baseline heparan sulfate cell surface expression levels were examined via flow cytometry analysis in nontumorigenic immortal mammary epithelial MCF-10A cells and TNBC MDA-MB 231, Hs 578t and MDA-MB 468 cells. The standard deviation was calculated from three independent experiments performed in triplicate. The student’s t-test was performed with * representing p<0.05 and ** representing p<0.01 comparing expression levels in MCF-10A to those in the TNBC cell lines. (C) The AMSBIO BR1202B breast cancer tissue array (120 cores with 82 TNBC cores; key can be found in Supplemental Figure 8C and corresponding Supplemental Table 1 showing breast cancer sub-type distribution) was stained with heparan sulfate.

Article Snippet: An AMSBIO breast cancer tissue array (120 cores specifically with 82 TNBC cores), two normal breast tissue slides and three DCIS tissue slides were stained with heparan sulfate specific antibody ( , Supplemental Figure 8) and statistical analysis was performed ( ).

Techniques: Expressing, Control, Enzyme-linked Immunosorbent Assay, Standard Deviation, Flow Cytometry, Staining

Journal: bioRxiv

Article Title: The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer

doi: 10.1101/2023.09.08.556819

Figure Lengend Snippet: (A) Pairwise comparisons using Dunn’s test indicated that there was a significant difference between TNBC and normal breast (p = 0.0040), TNBC and DCIS (p = 0.0359), ER+/PR+ and normal (p = 0.0209), and HER2+ and normal (p = 0.0403), in the percentage of heparan sulfate positively stained cells in the tissue sections. No other differences were significantly different. (B) Pairwise comparisons using Dunn’s test showed that there was a significant difference between TNBC and normal (p = 0.0048), TNBC and DCIS (p = 0.0416), ER+/PR+ and normal (p = 0.0131), and HER2+ and normal (p = 0.0321), in the percentage of heparan sulfate weakly stained cells. No other differences were significantly different. (C) Pairwise comparisons using Dunn’s test demonstrated that there was a significant difference between TNBC and normal (p = 0.0003), TNBC and DCIS (p = 0.0064), ER+/PR+ and normal (p = 0.0127), HER2+ and normal (p = 0.0041), and HER2+ and DCIS (p = 0.0305), in the percentage of heparan sulfate moderately stained cells. No other differences were significantly different. (D) Pairwise comparisons using Dunn’s test demonstrated that there was a significant difference between TNBC and Normal (p = 0.0001), TNBC and DCIS (p = 0.0020), ER+/PR+ and normal (p = 0.0002), ER+/PR+ and DCIS (p = 0.0087), HER2+ and normal (p = 0.0003), and HER2+ and DCIS (p = 0.0109), in the percentage of heparan sulfate strongly stained cells. No other differences were significantly different. (E) Pairwise comparisons using Dunn’s test demonstrated that there was a significant difference between TNBC and normal (p = 0.0040), TNBC and DCIS (p = 0.0359), ER+/PR+ and normal (p = 0.0209), HER2+ and normal (p = 0.0003), and HER2+ and normal (p = 0.0403), in the percentage of cells negative for heparan sulfate staining. No other differences were significantly different. (F) Kruskal-Wallis test indicated that there was no significant difference in the percentage of heparan sulfate positively stained cells in the tumor amongst the TNBC breast cancer stages.

Article Snippet: An AMSBIO breast cancer tissue array (120 cores specifically with 82 TNBC cores), two normal breast tissue slides and three DCIS tissue slides were stained with heparan sulfate specific antibody ( , Supplemental Figure 8) and statistical analysis was performed ( ).

Techniques: Staining

Journal: bioRxiv

Article Title: The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer

doi: 10.1101/2023.09.08.556819

Figure Lengend Snippet: (A) Baseline extracellular heparanase expression was determined in nontumorigenic immortal mammary epithelial MCF-10A cells and TNBC MDA-MB 231, Hs 578t and MDA-MB 468 cells by ELISAs. The standard deviation was calculated from three independent experiments performed in triplicate. The student’s t-test was performed with * representing p<0.05 and ** representing p<0.01, comparing expression levels in MCF-10A to those in the TNBC cell lines. (B) The AMSBIO BR1202B breast cancer tissue array (120 cores with 82 TNBC cores; key can be found in Supplemental Figure 8C and corresponding Excel worksheet showing breast cancer sub-type distribution) was stained with heparanase.

Article Snippet: An AMSBIO breast cancer tissue array (120 cores specifically with 82 TNBC cores), two normal breast tissue slides and three DCIS tissue slides were stained with heparan sulfate specific antibody ( , Supplemental Figure 8) and statistical analysis was performed ( ).

Techniques: Expressing, Standard Deviation, Staining

Journal: bioRxiv

Article Title: The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer

doi: 10.1101/2023.09.08.556819

Figure Lengend Snippet: Kruskal-Wallis test indicated that there was no significant difference: (A) in the percentage of heparanase positively stained cells in the tissue sections of normal breast tissue, DCIS and invasive breast cancer subtypes, (B) in the percentage of heparanase weakly stained cells in the tissue sections of normal breast tissue, DCIS and invasive breast cancer subtypes, (C) in the percentage of heparanase moderately stained cells in the tissue sections of normal breast tissue, DCIS and invasive breast cancer subtypes, (D) in the percentage of heparanase strongly stained cells in the tissue sections of normal breast tissue, DCIS and invasive breast cancer subtypes, (E) in the percentage of negative heparanase stained cells in the tissue sections of normal breast tissue, DCIS and invasive breast cancer subtypes and (F) in the percentage of heparanase positively stained cells in the tissue sections of different TNBC breast cancer stages.

Article Snippet: An AMSBIO breast cancer tissue array (120 cores specifically with 82 TNBC cores), two normal breast tissue slides and three DCIS tissue slides were stained with heparan sulfate specific antibody ( , Supplemental Figure 8) and statistical analysis was performed ( ).

Techniques: Staining

Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 1. The Expression of SELENBP1 in Normal and Tumor Breast Tissues. Breast cancer tissue arrays were stained by immunohistochemistry using anti-human SELENBP1 antibody at 1:100 dilution. Positive stained cells are shown in dark brown color. (A) Strong positive staining of SELENBP1 in normal breast tissue under low power view (200X). (B–C) Weak positive to negative staining of SELENBP1 in breast cancer tissues under high power view (400X). (D) The Allred scoring distributions of SELENBP1 expression in normal and tumor tissue groups. Inside lines represent means and standard deviations. *p,0.05. (E) Statistical results for the difference between normal and tumor tissues as analyzed by Kruskal-Wallis test. doi:10.1371/journal.pone.0063702.g001

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing, Staining, Immunohistochemistry, Negative Staining

Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 2. SELENBP1 Expression is Progressively Reduced in Advancing Clinical Stages in Breast Cancer Tissues. (A) The scoring distributions of SELENBP1 expression in normal tissues and tumor tissues at stage II and stage III. Inside lines represent means and standard deviations. **p,0.01. (B) Statistical results for the difference between normal and tumor tissues as analyzed by Kruskal-Wallis test. (C) Survival curves of breast cancer patients with respect to different SELENBP1 expression levels are shown at stage II and (D) stage III. Blue and red lines represent the SELENBP1-high and SELENBP1-low groups, respectively. doi:10.1371/journal.pone.0063702.g002

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing

Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 3. The Correlation of SELENBP1 Expression with ER, PR, and TP53 in Breast Cancer Tissues. (A) The scoring distributions of SELENBP1 expression in normal tissues and tumor tissues with ER+ and ER– status. The inside lines represent means and standard deviations. **p,0.01. The difference between normal and ER+ and ER– tumor tissues was analyzed by Kruskal-Wallis test and statistical results are shown (B). Survival curves of breast cancer patients with respect to different SELENBP1 expression are shown in ER+ group in (C). The blue line is the SELENBP1- high group and the red line is the SELENBP1-low group. The scoring distributions of SELENBP1 expression in normal and tumor tissues with PR+/PR–

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing